




The prevalence of the cardiovascular disease significantly affects the outcome of both cardiac and non-cardiac surgery, and 
perioperative cardiac morbidity is one of the leading causes of death following anesthesia and surgery.  The considerable 
incidence of myocardial infarction, congestive heart failure, myocardial ischemia, or serious dysrhythmias during the 
intraoperative or postoperative periods, has led many studies to examine medical factors and interventions for decreasing 
cardiac risk in patients with cardiovascular disease.  An extensive amount of work has focused on whether any one anesthetic 
agent or technique is particularly beneficial for patients with coronary artery disease.  Experimental studies conducted in our 
laboratory have clearly shown that volatile anesthetics may exert profound cardioprotection against myocardial ischemia 
and reperfusion injury.  This article examines the recent evidence about the importance of mitochondria, reactive oxygen 
species and the KATP channels in cardioprotective signaling by volatile anesthetics. Moreover, the article addresses 
current concepts and controversies regarding specific roles of the mitochondrial and the sarcolemmal KATP channels in 
anesthetic-induced preconditioning.
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The cardiac tissue is very sensitive to 
hypoxia and short periods of ischemia, 
and could lead to extensive and 
permanent tissue death. Interestingly, 
short periods of ischemia (ischemic 
preconditioning-IPC) can lead to 
a reduced severity of cardiac injury. 
IPC has been studied extensively 
for the past two decades and has 
resulted in the publication of many 
studies, which have signif icantly 
increased our understanding of the 
cellular mechanisms of ischemia and 
reperfusion injury.  IPC was initially 
described in 1986(1) by Murray et al, who 
demonstrated that four 5-min periods of 
coronary artery occlusion interspersed 
with 5 min periods of reperfusion 
before a prolonged coronary occlusion 
produced a reduction in myocardial 
infarct size in dogs.  Preconditioning 
could also be induced in humans 
undergoing percutaneous transluminal 
coronary angioplasty with a coronary 
occlusion of 2 min duration.(2)    
Many studies have shown that volatile 
anesthetics may precondition the 
myocardium against ischemia and 
infarction by activating the protective 
cellular mechanisms.  This phenomenon 
was termed the anesthetic-induced 
preconditioning (APC).  The cellular 
signaling of APC involves protein kinase 
C, protein tyrosine kinase, mitogen-
activated protein kinases, protein 
kinase B and the mitochondria.  Finally, 
APC involves ion channels, in particular 
the mitochondrial and the sarcolemmal 
KATP channels. The mechanisms in-
volved in APC have been a subject 
of several detailed review articles(3-
12).  Myocardial protection by volatile 
anesthetics is of clinical importance for 
patients with coronary artery disease 
because of their high morbidity and 
because of their mortality that is secon-
dary to perioperative myocardial ische-
mia.  The potentially beneficial effects 
of APC in patients have also been 
reported.(4,5,13-17)
Initially, the mechanisms by which volatile 
anesthetics exert protective actions on 
ischemic myocardium have previously 
been attributed to an improvement in 
the relation between myocardial oxygen 
 7www.signavitae.com
supply and demand.  For instance, 
our research has reported that volatile 
anesthetics are negative inotropes that 
decrease left ventricular contractility 
and depress sino-atrial nodal function. 
These actions decrease myocardial 
oxygen demand.(18,19)  Although a 
portion of the cardioprotective effects of 
volatile anesthetics following ischemia 
and reperfusion demonstrated in our 
laboratory may be attributed to a reduction 
in energy requirements and ultimate 
preservation of energy-dependent vital 
cellular processes, other studies have 
demonstrated this not to be necessary for 
cardioprotection.  For example, volatile 
anesthetics could exert cardioprotective 
effects even when administered during 
cardioplegic arrest and at reperfusion. 
Many components of the signaling 
pathway leading to cardioprotection 
are shared by ischemic and anesthetic 
preconditioning.   Our laboratory and 
other studies have identified a signaling 
cascade that involves ROS, G-protein 
coupled receptors, protein kinases 
and ATP-sensitive potassium (KATP) 
channels.(11,12,20-50)
Volatile anesthetics are very powerful 
agents in reducing infarct size and 
the ATP-sensitive potassium (KATP) 
channels have long been considered 
essential components of cardiac pre-
conditioning.  There are two types of 
KATP channels in cardiac myocytes: 
the mitochondrial (mitoKATP) cha-
nnel which is located in the inner 
mitochondrial membrane, and the 
sarcolemmal (sarcKATP) channel which 
is located in the plasma membrane. 
After the discovery of the mitoKATP 
channels in the inner mitochondrial 
membrane and development of se-
lective mito and sarcKATP channel 
inhibitors, evidence suggested that 
mitoKATP channels rather than the 
sarcKATP channels may play a more 
important role in cardioprotection. 
However, some of the recent studies 
that involved the use of sarcKATP-
specific inhibitors and genetic models 
of disrupted or knocked-out sarcKATP 
channel subunits indicated that the role 
of sarcKATP channel in cardioprotection 
should not be ignored.(51,52) 
We have demonstrated that isoflurane 
can stimulate KATP channels in isolated 
ventricular myocytes.(20,40,41,48,49,
53,54)  In addition, our laboratory has 
shown that the KATP channel agonist 
pinacidil exerts greater effects to open 
the KATP channel in myocytes that were 
previously subjected to isoflurane.  We 
also found that isoflurane may diminish 
the sensitivity of the KATP channels 
to inhibition by ATP and; therefore, 
increase the open state probability of the 
channel.(54)  Recent findings suggest 
that an opening of the mitochondrial 
KATP channels is critically involved in 
IPC and induces reversible oxidation of 
mitochondria matrix.(55-59)  Because 
the opening of mitochondrial KATP 
channels can dissipate the inner 
mitochondrial membrane potential 
established by the proton pump, our 
laboratory examined the effects of 
anesthetics on mitochondrial redox 
state by recording the fluorescence 
of FAD-linked enzymes.  Our results 
indicate that isoflurane and sevoflurane 
dose-dependently increase the flavo-
protein fluorescence.(29,30,34,35) 
Additional studies are being conducted 
in our laboratory to examine the human 
cardiac KATP channels using the 
artificial lipid bilayer.(60)
We have also examined the role of A1-
receptor stimulation in the enhancement 
of recovery of contractile function of 
stunned myocardium by isoflurane.(61) 
These and other studies suggest that 
isoflurane either directly activates A1 
receptors or indirectly enhances the 
sensitivity of A1-receptors to reduced 
amounts of endogenously released 
adenosine.(62)  This protection could 
be reversed by adenosine  receptor 
antagonists, by Gi protein blockers, PKC 
inhibitors, and KATP channel blockers. 
Therefore, it may be assumed that 
inhalational anesthetics could stimulate 
these receptors, proteins and signal 
transduction pathways including the 
KATP channels.  Because our research 
has demonstrated that cardioprotection 
by anesthetics is not accompanied by 
augmented release of adenosine, it 
could be postulated that these receptor 
signal transduction pathways and KATP 
may be sensitized to the subsequent 
protein/channel modulators.  
  While it is evident that mitochondria 
play a crucial role in the phenomenon 
of anesthetic preconditioning, our most 
recent studies indicate that both the 
sarcKATP and the mitoKATP channels 
are essential for the protection of 
myocytes from damage by oxidative 
stress since their inhibition completely 
abolished the protective effects of 
isoflurane preconditioning.  Specifically, 
activation of the sarcKATP channel was 
required for the cardioprotective effects 
of APC during the stress period but 
not during the preconditioning period. 
In contrast, activation of mitoKATP 
channel was found to be necessary 
during both isoflurane preconditioning 
and during exposure to oxidative stress. 
From these results it appears that 
although activation of both channels 
is important for the cardioprotective 
effects of preconditioning, each channel 
performs a distinct role: the sarcKATP 
channel acts as an effector, while the 
mitoKATP channel plays a dual role as 
a trigger and an effector.  The role of the 
mitoKATP channel as both a trigger and 
an effector, and the sarcKATP channel 
as the effector of preconditioning could 
be explained by the following sequence 
of events:  1. Exposure to isoflurane can 
directly activate mitoKATP channels 
resulting in changes in the mitochondrial 
bioenergetics producing a small burst of 
ROS.  2.  The ROS can activate cytosolic 
mediators such as PKC that translocate 
to the sarcolemma and phosphorylate 
the sarcKATP channel and sensitize it 
to opening.  3.  The primed sarcKATP 
channel opens sooner during sub-
sequent metabolic stress resulting 
in a greater K+ efflux, a more rapid 
repolarization of the cell membrane and 
action potential shortening, which leads 
to a decrease in cytosolic Ca2+ loading 
during ischemia/reperfusion.  This can 
reduce or prevent mitochondrial Ca2+ 
overload, a major trigger of the cell death 
pathway.  4.  The mitoKATP channel can 
also open during ischemia/reperfusion 
which may result in the depolarization 
of the inner mitochondrial membrane 
and thus further decrease driving force 
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for the mitochondrial Ca2+ entry and 
loading during ischemia/reperfusion. 
Conclusion
Results from our and other laboratories 
indicating that volatile anesthetics protect 
ischemic myocardium are important 
and clinical significant for patients with 
coronary artery disease.  It is very clear 
that their morbidity and mortality that is 
secondary to perioperative myocardial 
ischemia is disproportionately high. 
It is well documented that anesthetic 
preconditioning occurs and myocardium 
can be rendered resistant to ischemia 
and reperfusion injury for a prolonged 
period after a prior, brief exposure to a 
volatile anesthetic.  Anesthetic-induced 
protection has many similarities to 
ischemic preconditioning including 
a window of protection that has also 
been confirmed in patients undergoing 
coronary bypass graft and other sur-
geries.
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